Antacid use and subclinical interstitial lung disease: the MESA study. Issue 5 (19th May 2017)

• Record Type: Journal Article
• Authors: Restivo, Michaela D.; Podolanczuk, Anna; Kawut, Steven M.; Raghu, Ganesh; Leary, Peter; Barr, R. Graham; Lederer, David J.
• Is Part Of: European respiratory journal. Volume 49:Issue 5(2017)
• Publication Date: 2017-05-19
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02566-2016
• Languages: English
• ISSNs: 0903-1936

Abstract

Idiopathic pulmonary fibrosis (IPF), a prevalent fibrotic idiopathic interstitial lung disease (ILD), is thought to result from recurrent subclinical alveolar epithelial cell (AEC) injury followed by abnormal repair and fibrogenesis [1]. Gastro-oesophageal reflux disease (GORD) has been implicated in AEC injury in IPF [2]. GORD is a prevalent comorbidity in adults with IPF [3], and the gastric enzyme pepsin has been identified in bronchoalveolar lavage fluid of patients with acute IPF exacerbations [4], suggesting a role of micro-aspiration in disease progression. Proton pump inhibitor use is associated with a reduction in subclinical interstitial lung disease http://ow.ly/dbFN30aoRPf